Introduction
============

Nitric oxide, endogenously synthesized in the mammalian system by the nitric oxide synthases (NOS), continues to receive widespread attention for its multifunctional roles in both physiological and patho-physiological conditions. Under physiological conditions, nitric oxide exerts pleiotrophic effects in different tissues. For instances, within the vascular-endothelial system, nitric oxide functions as an effective vaso-relaxant \[[@b1]\]. However, when present in the central and peripheral nervous systems, nitric oxide functions as a neurotransmitter \[[@b2]\]. On the other hand, nitric oxide is an antitumoral and antimicrobial defense agent produced by immune and glial cells in the context of mammalian host immunity \[[@b3]\].

With a half-life of only 3--5 sec *in vivo*, nitric oxide can readily enter a cell or move between cells many times within this time span \[[@b4]\] and react with the heme group of guanylate cyclase (GC), triggering a conformational change in GC and the catalysis of guanosine-5′-triphosphate (GTP) to cyclic guanosine 3′,5′-monophosphate (cGMP) \[[@b4]\] and protein phosphorylation. GC activation is believed to be the main nitrergic signal transduction pathway. cGMP acts as a second messenger that activates protein kinase G 1 and 2, with the former involved in intracellular Ca^2+^ control and the latter regulating anionic influx, for example chloride \[[@b5], [@b6]\]. This transduction pathway can affect a broad range of proteins directly, for example phosphodiesterases of cyclic nucleotides and indirectly, for example protein kinase A, thus increasing the level of adenosine 3′,5′-monophosphate (cAMP) with activation of proteins involved in the cAMP downstream pathway \[[@b7], [@b8]\].

Nitric oxide is capable of affecting other cellular signalling pathways independent of GC activation. As nitric oxide is thermodynamically unstable, it is able to undergo various chemical reactions with gaseous molecules, anions and reactive oxygen species (ROS) to form nitrites, nitrates and peroxynitrites (ONOO^−^). Nitric oxide reacts quickly with the superoxide anion (O~2~•^−^) to form peroxynitrite (ONOO^−^) to avoid its elimination by the antioxidant systems. ONOO^−^ has an action radius of 100 μm and even shorter of half-life of 1--2 sec, tending to generate multiple toxic products in its degradation \[[@b9]\]. During the process of these chemical reactions, intermediate products such as (ROS) and other free radicals are produced. These nitrergic intermediate and end-products can induce modifications of lipids, proteins and DNA through oxidation \[[@b10]\], nitration \[[@b11]\] or nitrosylation \[[@b12]\].

The involvement of diverse functional nitric oxide in the nervous system continues to attract researchers' attention as its implication in various neurodegenerative disorders linked to oxidative stress, including ischaemia \[[@b13]\], amyotrophic lateral sclerosis \[[@b14]\], Alzheimer\'s disease (AD) \[[@b15]\] and Parkinson\'s disease (PD) \[[@b16]\]. The bi-phasic role of nitric oxide either as a physiological neuromodulator or a neurotoxic factor is dependent on the level of intracellular nitric oxide. Nitric oxide induced cytotoxicity is significantly elevated in pathological conditions implicating the generation of ROS and ONOO^−^ as a key mechanism in brain injury where they are both likely to mediate programmed cell death (PCD) \[[@b17], [@b18]\]. Moreover, iNOS induction by diverse stimuli such as endotoxins or cytokines and during excitotoxicity caused by constitutive activation of glutamate receptors can result in overproduction of nitric oxide because of increased nNOS activity \[[@b19]\]. Chronic Aß~1--40~ intracerebroventricular infusion in an AD model has been demonstrated to induce ONOO^−^ formation resulting in nitration of tyrosyl residues of proteins \[[@b20]\]. In ischaemia/reperfusion and stroke models, the higher nitric oxide level is accounted for by increased synthesis activity of iNOS and the constitutive isoforms of NOS triggered by elevated Ca^2+^ level \[[@b21]\]. However, the role of nitric oxide in ischaemia remains controversial. Inhibition of nitric oxide production in iNOS and nNOS knockout mice or by non-selective pharmacological inhibitor has demonstrated neuroprotective effects in models of cerebral ischaemia \[[@b22]\] and traumatic brain injury \[[@b23]\], respectively. On the contrary, \[[@b24]\] demonstrated that pre-treatment with NOS inhibitor aggravated neuronal death whereas post-treatment showed no neuronal rescue effect on cerebral ischaemia injury. In PD, inhibition of parkin \[[@b25]\] and glutathione reductase \[[@b26]\] activities by ONOO^−^-induced protein modification increased susceptibility to neuronal death as a result of lower cellular antioxidant defense.

As nitric oxide has widespread implications in the pathogenesis of numerous neurodegenerative diseases because of its toxic and undesirable interaction with ROS, an understanding of the mechanisms of nitric oxide mediated neuronal injury provides a screening platform for identification of potential universal biological targets involved in neuronal death. Our current study of the neuronal transcriptome revealed a stunning list of 3672 probe sets exhibiting transcriptional regulation of at least ±1.5-fold change in a minimum of one out of three time-points (8, 15 and 24 hrs) in nitric oxide mediated neuronal injury. Biological functional annotation of these genes revealed that multiple enriched biological processes were significantly regulated. Although some of these over-represented pathways have been documented to a degree, many are novel providing unique insights into nitric oxide related neuronal injury, enabling us to define the temporal profile of recruitment of death signalling.

Materials and methods
=====================

Materials
---------

Neurobasal™ (NB) medium, B-27 and GlutaMAX supplements were from Invitrogen/GIBCO™ (Carlsband, CA, USA). Cell culture plates were from NUNC (Naperville, IL, USA). NOC-18 (DETA-NONOate, (*Z*)-1-\[[@b2]-([@b2]-Aminoethyl)-*N*-([@b2]-ammonioethyl)amino\]diazen-1-ium-1,2-diolate from Alexis Biochemical (San Diego, CA, USA). The primary antibodies used in Western blot analysis were as follows: active caspase-3 antibody from BD Biosciences PharMingen (San Diego, CA, USA); α-fodrin antibody from Chemicon (Temecula, CA, USA) and β-tubulin antibody from Cytoskeleton (St. Denver, CO, USA). All other nutrients, salts and antibiotics used in the culture media or assay buffers were from Sigma (Singapore).

Cell culture preparation for murine primary cortical neurons
------------------------------------------------------------

The primary cultures were prepared by using neocortical neurons (gestational days 15 or 16) obtained from foetal cortices of Swiss albino mice following previous described procedures with modifications \[[@b27]\]. Microdissected cortices were subjected to trypsin digestion and mechanical trituration. Cells were collected by centrifugation and resuspended in NB medium containing 2.5% B-27 supplement, 1% penicillin, 1% streptomycin, 0.25% GlutaMAX-1 supplement and 10% dialysed foetal calf serum. Twenty-four well plates previously coated with poly-[d]{.smallcaps}-lysine (100 μg/ml) were seeded with cells at a density of 2 × 10^5^ cells/cm^2^ and used for subsequent experiments. The cultures were maintained at 37°C overnight in a humidified 5% CO~2~ and 95% air incubator and the culture media changed to a serum-free NB medium containing all previously mentioned constituents. Immunocytochemical staining for microtubule-associated protein-2 and glia fibrillary acidic protein revealed more than 95% of the cells in day 5 *in vitro* cultures were neurons with minimal contamination by glia \[[@b27]\]. All experiments involving animals were approved by the National University of Singapore (Protocol no. 727/05) and were in accordance with the Ethical principles and guidelines for scientific experiments on animals' of the Swiss Academy of Medical Sciences.

Drug preparation and treatment
------------------------------

Nitric oxide donor, NOC-18 was prepared as 100 mM aqueous stock solution containing 0.01 M sodium hydroxide (NaOH) and stored at --20°C. On day 7 *in vitro*, the cultured neurons were treated with respective drug in NB medium.

Hoechst stain
-------------

Cells were fixed with 4% paraformaldehyde in phosphate buffered saline. Fixed cells were then incubated with Hoechst 33342 at the final concentration of 2 μg/ml. Stained nuclei were observed and analysed under a fluorescence microscope (Leica DM IRB).

Qualitative and quantitative analysis of cell viability
-------------------------------------------------------

The 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was employed as index of cell survival \[[@b27]\]. MTT was dissolved at a stock concentration of 5 mg/ml in RPMI-1640 medium (GIBCO). Thirty microlitres of MTT solution was added to each well of the 24-well plate containing 300 μl culture medium. After incubation at 37°C for 20 min, the culture medium was removed by aspiration. The formazan formed in the wells was dissolved by an aliquot of 200 μl DMSO and the absorbance of the solution was read using a TECAN plate reader at a wavelength of 570 nm. Results from MTT assay are presented as mean ± S.E.M. from three independent experiments.

Western blotting
----------------

Cells were lysed with RIPA buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% Nonidet-P40, 0.5% deoxycholate, 0.1% SDS, protease inhibitor cocktail tablet) and spun down at 16,000 × *g* for 10 min to obtain the supernatants whose concentrations were quantitated using Biorad RC-DC assay. Ten micrograms of proteins from individual supernatant samples containing 1× SDS (with 20% freshly added β-mercaptoethanol) were heated to 100°C for 5 min, cooled down to room temperature and subsequently centrifuged for 2 min at 16,000 × *g*. Equal amount of protein was loaded and subjected to SDS-PAGE (12% gel) and immunoblotted using commercially available antibodies. Antitubulin (1:1000; Cytoskeleton Inc., St. Denver, CO, USA) monoclonal antibody was used for internal control purpose. Antibody-reactive bands were detected using chemiluminescence (Pierce Biotechnology Inc., Rockford, IL, USA) and exposure to x-ray film (Eastman Kodak Company, Rochester, New York, USA).

Total RNA extraction and isolation
----------------------------------

RNA from samples was extracted using RNeasy Mini Kit (Qiagen Cat. No. 74104) according to the manufacturer\'s instructions. All pipette tips used were RNase-free and with filters. The following procedures were suited for 1 × 10^6^ cultured cells per sample. 1.5 μl of the RNA sample was aliquoted for spectrophotometric quantification using Nanodrop ND-1000 Version 3.2.1 and 1 μl for RNA quality analysis using E-gene HDA-GT12 genetic analyser.

Affymetrix microarray using Affymetrix® GeneChip Mouse Genome 430 2.0 array
---------------------------------------------------------------------------

Microarray analysis was carried out using 14 GeneChip Mouse Genome 430 2.0 array (Affymetrix, Santa Clara, CA, USA), which contain 45,000 probe sets and can analyse the expression level of over 39,000 transcripts and variants from over 34,000 well-characterized mouse genes. The assignment of the arrays (GeneChip) was as follows: vehicle-treated control (*n* = 5); NOC-18-treatment for 8, 15 and 24 hrs NOC-18 treatment (*n* = 3 for each time-point).

According to technical manual form Affymetrix, 7 μg of extracted total RNA was used for cDNA synthesis. Double-stranded cDNA was synthesized using Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA) with a T7-dT24 primer. After cleanup, Biotin-labelled cRNA was synthesized by *in vitro* transcription (Enzo Diagnostic, Inc., NY, USA) and fragmented subsequently. Fifteen micrograms of fragmented cRNA produced above was hybridized to the arrays for 16 hrs at 45°C. The hybridized arrays were washed, stained, and scanned according to the manufacturer\'s instructions. The data from each array were collected and initially analysed using Affymetrix Microarray Suite 5.0 software. For comparison of multiple arrays, the signal intensity of each array was scaled to 500. The regulated genes were filtered on fold change 1.5-fold against controls in at least one of three time-points. One-way [anova]{.smallcaps} (*P* \< 0.05) approach was used to find differentially expressed genes using GeneSpring™ GX 7.3 software (Agilent Technologies, CA, USA). Functional information about each gene product was obtained from web-based database NetAffx (3′ IVT Expression, Affymetrix), web-based applications DAVID 2008 (<http://david.abcc.ncifcrf.gov/>) and from direct searches of the primary literature (PubMed: <http://www.ncbi.nlm.nih.gov/pubmed/>).

Microarray bioinformatics analysis
----------------------------------

The absolute data (signal intensity, detection call and detection *P* value) were exported into GeneSpring^(tm)^ GX 7.3 (Agilent Technologies, San Diego, CA, USA) software for analysis by parametric test based on crossgene error model. One-way [anova]{.smallcaps} approach was used to identify differentially expressed genes. Array data were globally normalized using GeneSpring software. After per chip normalizations and per gene normalization, genes were filtered on fold change ±1.5-fold against controls in at least one of three conditions. Finally, one-way [anova]{.smallcaps} approach (*P* \< 0.05) and Benjamini-Hochberg FDR Correction were used to find differentially expressed genes. Genes which were differentially expressed are annotated using Database for Annotation, Visualization, and Integrated Discovery (DAVID) V6.7 (<http://david.abcc.ncifcrf.gov/>) and PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>) search. All microarray data reported here is described in accordance with MIAME guidelines and has been deposited in NCBIs Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) and are accessible through GEO Series accession number GSE22087 for nitric oxide global transcriptomic profile.

Real-time PCR
-------------

Reverse transcription was carried out according to steps specified by manufacturer (Applied Biosystems Taqman reverse transcription reagents). Each cDNA sample was duplicated with two No Template Control (NTC) for each probe used. Twenty microlitres of the Taqman master mix was pipetted to the bottom of each well of the optical 96-well fast reaction plate. Five microlitres of cDNA or water (NTC) was added to the designated reaction well. The plate was then read by the 7000 Fast Real-Time PCR System with conditions according to the manufacturer\'s protocol.

Statistical analysis
--------------------

Values are mean ± S.E.M. of at least three independent experiments. Data were analysed using Tukey test with one-way [anova]{.smallcaps} to assess significant differences in multiple comparisons. Values of *P* \< 0.05 were considered as statistically significant and presented as mean ± S.E.

Results
=======

Nitric oxide induced apoptotic cell death in cultured primary neurons
---------------------------------------------------------------------

High doses of nitric oxide, frequently observed in the pathogenesis of neurodegenerative disease, cause neuronal death. In this study, we adopt a neuronal model of cultured day 7 murine primary cortical neurons. Cell viability assay demonstrated a concentration-dependent decrease in cell viability after 24 hrs treatment with NOC-18 (a nitric oxide donor; [Fig. 1A](#fig01){ref-type="fig"}). As determined from [Figure 1A](#fig01){ref-type="fig"}, the IC~50~ for nitric oxide was 0.5 mM (51.2 ± 4.0% cell viability). Morphological analysis of 0.5 mM NOC-18-treated neurons by Hoffman modulation contrast imaging demonstrated cell shrinkage into round apoptotic cell bodies with absence of neuritic outgrowths and \[[Fig. 1B(ii)](#fig01){ref-type="fig"}\] when compared to the healthy control neurons \[[Fig. 1B(i)](#fig01){ref-type="fig"}\]. There was an absence of rapid swelling indicating that accidental necrosis was not involved \[[@b18]\]. In addition, Hoescht stain illustrated the presence of chromatin condensation in these round cell bodies \[[Fig. 1B(iv)](#fig01){ref-type="fig"}\] as opposed to that of control cells \[[Fig. 1B(iii)](#fig01){ref-type="fig"}\], further confirming induction of neuronal death predominantly by apoptotic-like injury by 0.5 mM of NOC-18. In this study, 0.5 mM of NOC-18 was chosen for subsequent time-course experiments.

###### 

\(A\) Cell viability assay revealed a dose-dependent increase in neuronal death of NOC-18-treated primary cortical neurons. Day 7 murine primary cortical neurons were treated with NOC-18, A nitric oxide donor, at various concentrations. MTT assay was conducted 24 hrs later. Data are representative of three independent experiments performed in replicates (\**P* \< 0.05 as compared with the control). (B) Round shrunken apoptotic bodies with chromatin condensation were observed in nitric oxide induced neuronal injury. Hoffman imaging of control (i) and 0.5 mM NOC-18-treated (ii) primary cortical neurons was performed after 24 hrs post-treatment (Top). Hoechst nuclei stain was subsequently carried out to reveal extent of chromatin condensation in control (iii) and nitric oxide treated (iv) neurons (Bottom). Each scale bar represents 10 μm. Data are representative of three independent experiments.
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To understand the nature of nitric oxide induced neuronal injury, immunoblot analysis against inactive pro-caspase-3 (32 kD) and active caspase-3 (made up of a 12 and 17 kD subunits) was conducted. [Figure 2A](#fig02){ref-type="fig"} demonstrated a time-dependent increase in caspase-3 activation, with prominent overexpression of the active 17 kD subunit observed after 15 hrs post-treatment. Caspase-3 activation was further confirmed by the presence of the 120 kD truncated α-fodrin fragment from 15 hrs post-treatment ([Fig. 2B](#fig02){ref-type="fig"}). Expression of the 145/150 kD α-fodrin protein fragment also suggested the presence of calcium-activated calpains activation in nitric oxide induced neuronal injury ([Fig. 2B](#fig02){ref-type="fig"}). These data are suggestive of PCD, which is slow in onset and involves the recruitment of multiple proteases \[[@b18]\].

###### 

\(A\) Immunoblotting against pro- and active caspase-3 revealed caspase-3 activation at 15 hrs after 0.5 mM NOC-18 treatment. Pro-caspase-3, a 32 kD pro-enzyme is cleaved into two functional subunits of 17 and 11 kD, respectively, to form the active caspase-3 complex. (B) Immunoblotting against α-fodrin demonstrated simultaneous caspase-3 and calpains activation at 15 hrs after 0.5 mM NOC-18 treatment. α-Fodrin, a common substrate to both caspase-3 and calpains, is cleaved to 120 kD and 145/150 kD protein fragments upon caspase-3 and calpains activation, respectively. Initial expression of the 120 and 145/150 kD occurred at 15 hrs post-NOC-18 treatment on murine primary cortical neurons. Cultured neurons were treated with 0.5 mM NOC-18 and samples harvested with RIPA buffer from 4 to 24 hrs post-treatment. Ten micrograms of supernatent proteins from individual treatment was loaded in each lane and subjected to SDS-PAGE and immunoblotting analysis. Staurosporine (STA), a broad-spectrum kinase inhibitor, is well known for its role in induction of mito-chondrial-dependent caspase-3-mediated neuronal death and is in this case used as a positive control for neuronal treatment at 0.5 μM. Each immunoblot is representative of three independent analyses.
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Gene expression in nitric oxide induced neuronal apoptosis
----------------------------------------------------------

Affymetrix GeneChip Mouse Genome 430 V2.0 arrays were used to perform the microarray experiment on day 7 murine primary cortical neurons treated with 0.5 mM of NOC-18 over a time-course of 8, 15 and 24 hrs. All differentially expressed genes in this study were selected based on criteria of a minimum of ±1.5-fold change in at least one of three time-points and subjected to statistical testing by one-way [anova]{.smallcaps}, *P* \< 0.05 and Benjamini-Hochberg False Discovery Rate (FDR) Correction using GeneSpring v7.3 software. FDR, a commonly adopted statistical analysis, controls the proportion of the most relevant errors among those tests whose null hypothesis were rejected.

Out of a total of 45,000 probe sets representing over 34,000 well-characterized mouse genes, 3,672 microarray chip-annotated probe sets were profiled after 0.5 mM NOC-18 treatment ([Fig. 3A](#fig03){ref-type="fig"}). As demonstrated in [Figure 3A](#fig03){ref-type="fig"}, the number of down-regulated genes at individual time-points in NOC-18 treatment substantially overwhelmed the up-regulated genes. Across the three time-points, close to 30% of total gene probes demonstrated transcriptional up-regulation above the basal level of 1.0-fold. Within these up-regulated gene probes, the number of genes with fold-change difference above 1.5 significantly increases from 49% (8 hrs) to 96% (24 hrs). This tremendous increase was attributed to the expansion of the ≥2-fold change category from the initial 22% (8 hrs) to an escalating 58% (15 hrs), and continued on a slow steady increase to 73% (24 hrs). A similar trend was also observed for the down-regulated gene probes ([Fig. 3](#fig03){ref-type="fig"}). As such, it can be inferred that the most significant transcriptional regulation occurred between 8 and 15 hrs.

![Time-course profiling revealed a significant increase in number of up/down-regulated genes with transcriptional expression ≥twofold change from 8 to 24 hrs timeframe. Only genes with transcriptional fold-change of at least ±1.5 in at least one out of three time-points and had passed stringent statistical analysis (one-way [anova]{.smallcaps}, *P* \< 0.05) were included into nitric oxide global gene profile (a total of 3672 gene probes). Genes were then segregated into fold-change categories at respective time-points.](jcmm0016-0041-f3){#fig03}

The global gene profile list representative of NOC-18-mediated neuronal injury (3672 microarray chip-annotated probes sets) was then subjected to functional-gene ontology classification by DAVID 6.7 analysis \[[@b28], [@b29]\]. DAVID interpretation recognized 3484 biologically and functionally reported genes from various biological databases for nitric oxide treatment (as shown in [Fig. 4](#fig04){ref-type="fig"}).

![Flowchart of microarray analyses and profiling of neuronal death-related differentially expressed genes in nitric oxide mediated neuronal injury.](jcmm0016-0041-f4){#fig04}

To derive inferences pertaining to the temporal recruitment of cellular pathways and functional processes were altered, we performed a more structured over-representation analyses on the identified genes. The 3484 differentially expressed annotated genes were then classified into time-point-specific up/down-regulated categories based on (1) their fold-change above/below 1.5 at the specific time-point; and (2) if fold-change at the time-point is between --1.5 and 1.5, the inter-time-point up/down regulatory trend. This is to facilitate the identification of the temporal recruitment and/or activation/inhibition of biological pathways during nitric oxide mediated neuronal injury. To assess if a biological process was statistically significantly enriched, DAVID in-built Expression Analysis Systematic Explorer (EASE) program was employed. It categorizes genes to functional categories within the gene ontology hierarchical database and denotes which categories in the biological process ontology are statistically over-represented by identified genes. A *P* value \< 0.05 for a functional category denotes significant overrepresentation, and 0.05 ≤ *P* values ≤ 0.15 were considered borderline significant.

Despite the vast, useful information that DAVID has interpreted from the global gene profile, its structure is inadequate in providing additional associations (*e.g.* cell type and pathway targets). To complicate matter, many annotated genes on the microarray chip have not yet been fully associated with categories in the appropriate gene ontology hierarchies. This would explain the discrepancy in the number of annotated probe sets between the microarray chip (3672) and the DAVID (3484) defined groups. Consequently, we further substantiate the pathway/process analyses with in-depth literature review to identify and include additional clusters of genes with known pathway associations in either the identified DAVID gene-ontology categories or the comprehensive identified-gene lists that were not found by the analyses. The overall approach to derive inferences from global gene profiles has been previously documented in several microarray articles \[[@b30]--[@b32]\].

In this study, we focus on the over-represented biological processes (with EASE-determined *P* \< 0.05) induced in nitric oxide mediated neuronal injury ([Table 1](#tbl1){ref-type="table"}) and some of which are listed later. For the purpose of clear distinction during reference to proteins and genes, gene symbols in the text are in italics.

###### 

Selected differentially expressed gene profile of neuronal death-related families in cultured day 7 mouse primary cortical neurons treated with 0.5 mM NOC-18

  **GenBank**                             **Gene title**                                                                                   **Symbol**    **8 hrs**             **15 hrs**            **24 hrs**
  --------------------------------------- ------------------------------------------------------------------------------------------------ ------------- --------------------- --------------------- ---------------------
  NM_010019                               Death-associated protein kinase 2                                                                Dapk2         5.00 ± 0.47           5.05 ± 0.56           2.02 ± 1.05
  NM_020581                               Angiopoietin-like 4                                                                              Angptl4       1.28 ± 0.41           6.28 ± 1.45           2.63 ± 0.57
  NM_133810                               Serine/threonine kinase 17b (apoptosis-inducing)                                                 Stk17b        1.84 ± 0.34           3.28 ± 0.71           1.97 ± 0.73
  NM_054056                               PRKC, apoptosis, WT1, regulator                                                                  Pawr          1.61 ± 0.34           3.22 ± 0.66           2.32 ± 0.55
  NM_013929                               SIVA1, apoptosis-inducing factor                                                                 Siva1         −1.12 ± 0.35          1.95 ± 0.48           2.27 ± 0.55
  NM_009754                               BCL2-like 11 (apoptosis facilitator)                                                             Bcl2l11       3.04 ± 0.95           4.90 ± 0.78           7.28 ± 1.39
  NM_013749                               Tumour necrosis factor receptor superfamily, member 12a                                          Tnfrsf12a     2.86 ± 0.91           10.82 ± 0.93          17.99 ± 0.56
  NM_146057                               Death-associated protein                                                                         Dap           −1.22 ± 0.32          2.09 ± 0.48           2.28 ± 0.54
  NM_019740                               Forkhead box O3                                                                                  Foxo3         1.10 ± 0.31           1.65 ± 0.48           1.82 ± 0.54
  NM_019980                               LPS-induced TN factor                                                                            Litaf         1.23 ± 0.32           1.95 ± 0.48           1.96 ± 0.57
  NM_009068                               Receptor (TNFRSF)-interacting serine-threonine kinase 1                                          Ripk1         1.18 ± 0.37           1.50 ± 0.59           1.70 ± 0.56
  Cell survival, growth and development                                                                                                                  ▴27, *P* = 0.048      ▴49, *P* = 0.13       ▴48, *P* = 0.20
                                                                                                                                                         ▾47, *P* = 0.092      ▾ 65, *P* = 0.10      ▾ 65, *P* = 0.09
  NM_011632                               Tnf receptor-associated factor 3                                                                 Traf3         1.55 ± 0.42           4.91 ± 0.82           4.45 ± 0.59
  NM_011633                               Tnf receptor-associated factor 5                                                                 Traf5         1.58 ± 0.56           1.12 ± 0.58           1.87 ± 0.63
  NM_007566                               Baculoviral IAP repeat-containing 6                                                              Birc6         1.01 ± 0.66           1.59 ± 0.66           1.74 ± 0.69
  NM_007540                               Brain derived neurotrophic factor                                                                Bdnf          3.51 ± 0.32           2.50 ± 0.49           2.05 ± 0.56
  NM_010014                               Disabled homologue 1 (*Drosophila*)                                                              Dab1          1.74 ± 0.31           2.58 ± 0.48           3.84 ± 0.54
  NM_007912                               Epidermal growth factor receptor                                                                 Egfr          2.57 ± 0.32           3.39 ± 0.65           1.17 ± 0.54
  NM_010207                               Fibroblast growth factor receptor 2                                                              Fgfr2         2.11 ± 0.31           1.78 ± 0.48           1.40 ± 0.54
  NM_184052                               Insulin-like growth factor 1                                                                     Igf1          2.57 ± 0.43           3.98 ± 0.54           4.69 ± 0.59
  NM_010788                               Methyl CpG binding protein 2                                                                     Mecp2         2.89 ± 0.45           3.94 ± 1.53           4.97 ± 0.60
  NM_013613                               Nuclear receptor subfamily 4, group A, member 2                                                  Nr4a2         4.40 ± 0.31           4.04 ± 0.75           4.67 ± 0.54
  NM_153529                               Neuritin 1                                                                                       Nrn1          1.72 ± 0.31           1.89 ± 0.49           2.05 ± 0.54
  NM_013625                               Platelet-activating factor acetylhydrolase, isoform 1b, 1 subunit                                Pafah1b1      1.32 ± 0.31           1.77 ± 0.48           2.74 ± 0.54
  NM_009367                               Transforming growth factor-β2                                                                    Tgfb2         2.53 ± 0.44           2.15 ± 0.55           1.07 ± 0.63
  NM_009715                               Activating transcription factor 2                                                                Atf2          1.45 ± 0.31           1.28 ± 0.49           2.25 ± 0.54
  NM_139294                               Braf transforming gene                                                                           Braf          1.33 ± 0.33           1.46 ± 0.49           2.05 ± 0.56
  NM_007700                               Conserved helix-loop-helix ubiquitous kinase                                                     Chuk          1.09 ± 0.32           2.12 ± 0.48           1.84 ± 0.55
  NM_021461                               MAP kinase-interacting serine/threonine kinase 1                                                 Mknk1         2.07 ± 1.32           3.95 ± 1.08           2.70 ± 0.88
  NM_013672                               Trans-acting transcription factor 1                                                              Sp1           1.11 ± 0.31           1.70 ± 0.49           1.75 ± 0.54
  NM_010234                               FBJ osteosarcoma oncogene                                                                        Fos           31.00 ± 1.08          21.65 ± 5.39          16.78 ± 0.81
  NM_008036                               FBJ osteosarcoma oncogene B                                                                      Fosb          29.07 ± 1.36          13.76 ± 4.48          7.25 ± 1.53
  NM_010591                               Jun oncogene                                                                                     Jun           8.63 ± 0.34           6.99 ± 1.18           7.48 ± 0.54
  NM_008416                               Jun-B oncogene                                                                                   Junb          7.48 ± 0.76           6.07± 0.69            3.86 ± 0.54
  Mitotic cell cycle regulation                                                                                                                          ▴35, P 1.1 ^−5^       ▴26, P 4.1 ^−4^       ▴19, P 0.14
                                                                                                                                                         ▾51, *P* = 6.0 ^−4^   ▾ 54, P 5.2 ^−5^      ▾54, P 4.5 ^−5^
  NM_023813                               Calcium/calmodulin-dependent protein kinase II, delta                                            Camk2d        2.38 ± 0.35           6.23 ± 0.49           4.76 ± 0.69
  NM_009828                               Cyclin A2                                                                                        Ccna2         1.28 ± 0.31           1.73 ± 0.48           −1.70 ± 0.54
  NM_172301                               Cyclin B1                                                                                        Ccnb1         1.34 ± 0.33           1.82 ± 0.49           −3.18 ± 0.54
  NM_009831                               Cyclin G1                                                                                        Ccng1         1.13 ± 0.44           2.55 ± 0.48           4.27 ± 1.07
  NM_019937                               Cyclin L1                                                                                        Ccnl1         1.19 ± 0.31           1.94 ± 0.48           1.61 ± 0.54
  NM_023223                               Cell division cycle 20 homologue (*S. cerevisiae*)                                               Cdc20         1.05 ± 0.31           1.66 ± 0.57           −1.76 ± 0.55
  NM_145436                               Cell division cycle 27 homologue (*S. cerevisiae*)                                               Cdc27         1.32 ± 0.32           1.47 ± 0.48           2.12 ± 0.54
                                                                                                                                                                                                     
  NM_027118                               Cell division cycle 2-like 5 (cholinesterase-related cell division controller)                   Cdc2l5        2.31 ± 0.44           3.77 ± 0.49           4.34 ± 0.57
  NM_009874                               Cyclin-dependent kinase 7 (homologue of Xenopus MO15 cdk-activating kinase)                      Cdk7          1.12 ± 0.31           1.52 ± 0.48           1.87 ± 0.54
  NM_026014                               Chromatin licensing and DNA replication factor 1                                                 Cdt1          1.33 ± 0.31           1.83 ± 0.48           2.81 ± 0.56
  NM_007862                               Discs, large homologue 1 (*Drosophila*)                                                          Dlg1          1.06 ± 0.32           1.39 ± 0.48           1.85 ± 0.54
  NM_013642                               Dual specificity phosphatase 1                                                                   Dusp1         2.13 ± 0.31           2.30 ± 0.48           1.91 ± 0.54
  NM_007893                               E4F transcription factor 1                                                                       E4f1          1.20 ± 0.32           1.65 ± 0.48           2.05 ± 0.54
  NM_011808                               E26 avian leukemia oncogene 1, 5′ domain                                                         Ets1          1.86 ± 0.49           2.67 ± 0.57           1.95 ± 0.62
  NM_183186                               Forkhead box N3                                                                                  Foxn3         1.45 ± 0.32           1.62 ± 0.48           −1.00 ± 0.55
  NM_007836                               Growth arrest and DNA-damage-inducible 45α                                                       Gadd45a       1.31 ± 0.85           5.09 ± 0.87           9.65 ± 0.80
  NM_008655                               Growth arrest and DNA-damage-inducible 45β                                                       Gadd45b       3.68 ± 0.35           7.48 ± 0.99           5.72 ± 1.35
  NM_011817                               Growth arrest and DNA-damage-inducible 45λ                                                       Gadd45g       5.46 ± 0.31           9.09 ± 1.30           8.80 ± 0.54
  NM_007569                               B-cell translocation gene 1, antiproliferative                                                   Btg1          1.44 ± 0.31           1.95 ± 0.48           1.75 ± 0.55
  NM_007570                               B-cell translocation gene 2, antiproliferative                                                   Btg2          4.20 ± 0.37           5.75 ± 1.22           6.65 ± 0.96
  NM_009770                               B-cell translocation gene 3                                                                      Btg3          2.96 ± 0.31           5.53 ± 0.84           5.14 ± 0.54
  NM_007669                               Cyclin-dependent kinase inhibitor 1A (p21)                                                       Cdkn1a        −1.23 ± 0.31          1.73 ± 0.48           2.24 ± 0.54
  NM_007670                               Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)                                        Cdkn2b        1.51 ± 0.34           1.85 ± 0.50           1.76 ± 0.63
  NM_173378                               Transformation-related protein 53 binding protein 2                                              Trp53bp2      1.24 ± 0.31           1.19 ± 0.48           1.85 ± 0.54
  NM_010786                               Transformed mouse 3T3 cell double minute 2                                                       Mdm2          −1.03 ± 0.31          1.68 ± 0.48           2.38 ± 0.54
  NM_008575                               Transformed mouse 3T3 cell double minute 4                                                       Mdm4          1.38 ± 0.36           1.74 ± 0.50           2.63 ± 0.57
  NM_001003918                            Ubiquitin specific peptidase 7                                                                   Usp7          1.31 ± 0.33           1.88 ± 0.48           1.48 ± 0.55
  NM_175089                               NIMA (never in mitosis gene a)-related expressed kinase 1                                        Nek1          1.08 ± 0.66           1.58 ± 0.67           1.65 ± 0.77
  NM_021606                               NIMA (never in mitosis gene a)-related expressed kinase 6                                        Nek6          1.31 ± 0.31           2.10 ± 0.48           2.39 ± 0.54
  NM_010937                               Neuroblastoma ras oncogene                                                                       Nras          1.08 ± 0.31           1.97 ± 0.48           2.88 ± 0.54
  NM_009174                               Seven in absentia 2                                                                              Siah2         1.60 ± 0.32           1.31 ± 0.49           2.40 ± 0.54
  NM_022021                               CDK5 and Abl enzyme substrate 1                                                                  Cables1       −1.42 ± 0.36          −1.90 ± 0.51          −1.84 ± 0.56
  NM_016746                               Cyclin C                                                                                         Ccnc          −1.87 ± 0.32          −2.44 ± 0.49          −5.40 ± 0.55
  NM_007631                               Cyclin D1                                                                                        Ccnd1         −2.44 ± 0.31          −1.34 ± 0.48          −1.99 ± 0.55
  NM_009829                               Cyclin D2                                                                                        Ccnd2         −1.79 ± 0.31          −1.38 ± 0.48          −2.44 ± 0.54
  NM_009830                               Cyclin E2                                                                                        Ccne2         −2.22 ± 0.34          −1.92 ± 0.49          −2.23 ± 0.55
  NM_007634                               Cyclin F                                                                                         Ccnf          −1.21 ± 0.50          −1.96 ± 0.62          −2.13 ± 0.65
  NM_023243                               Cyclin H                                                                                         Ccnh          −2.36 ± 0.31          −1.82 ± 0.48          −2.24 ± 0.54
  NM_172839                               Cyclin J                                                                                         Ccnj          −1.35 ± 0.32          −1.72 ± 0.48          −2.18 ± 0.54
  NM_001045530                            Cyclin J-like                                                                                    Ccnjl         −1.75 ± 0.32          −1.78 ± 0.48          −3.95 ± 0.55
  NM_001080818                            CDC14 cell division cycle 14 homologue A (*S. cerevisiae*)                                       Cdc14a        −1.52 ± 0.44          −1.30 ± 0.55          −5.73 ± 0.64
  NM_178347                               CDC23 (cell division cycle 23, yeast, homologue)                                                 Cdc23         −1.41 ± 0.31          −2.13 ± 0.48          −2.42 ± 0.54
  NM_007658                               Cell division cycle 25 homologue A (*S. pombe*)                                                  Cdc25a        −1.44 ± 0.32          −1.75 ± 0.49          −3.21 ± 0.54
  NM_139291                               Cell division cycle 26                                                                           Cdc26         −1.43 ± 0.31          −1.81 ± 0.48          −2.36 ± 0.54
  NM_025950                               Cell division cycle 37 homologue (*S. cerevisiae*)-like 1                                        Cdc37l1       −1.27 ± 0.32          −1.88 ± 0.48          −1.93 ± 0.55
  NM_013538                               Cell division cycle associated 3                                                                 Cdca3         −1.00 ± 0.32          −1.45 ± 0.49          −8.16 ± 0.54
  NM_016756                               Cyclin-dependent kinase 2                                                                        Cdk2          −1.29 ± 0.32          −1.79 ± 0.49          −2.15 ± 0.55
  NM_009873                               Cyclin-dependent kinase 6                                                                        Cdk6          −1.19 ± 0.32          −1.91 ± 0.48          −3.65 ± 0.54
  NM_009874                               Cyclin-dependent kinase 7 (homologue of Xenopus MO15 cdk-activating kinase)                      Cdk7          −2.10 ± 0.35          −2.56 ± 0.52          −9.89 ± 0.55
  NM_172717                               Checkpoint with forkhead and ring finger domains                                                 Chfr          −1.12 ± 0.31          −2.17 ± 0.48          −2.03 ± 0.54
  NM_010093                               E2F transcription factor 3                                                                       E2f3          −2.13 ± 0.31          −2.72 ± 0.48          −2.32 ± 0.54
  NM_146066                               G1 to S phase transition 1                                                                       Gspt1         −1.43 ± 0.31          −2.19 ± 0.48          −2.80 ± 0.54
  NM_026933                               TP53-regulated inhibitor of apoptosis 1                                                          Triap1        −1.38 ± 0.31          −1.93 ± 0.48          −1.55 ± 0.54
  Endoplasmic reticulum (ER) stress                                                                                                                      ▴6, *P* = 3.2 ^−3^    ▴6, *P* = 2.2 ^−3^    ▴6, *P* = 1.9 ^−3^
                                                                                                                                                         ▾5, *P* = 0.44        ▾5, *P* = 0.42        ▾5, *P* = 0.42
  NM_009883                               CCAAT/enhancer binding protein (C/EBP),                                                          Cebpb         2.47 ± 0.65           4.10 ± 0.49           3.53 ± 0.55
  NM_007837                               DNA-damage inducible transcript 3                                                                Ddit3         2.12 ± 0.66           5.75 ± 0.48           7.10 ± 0.79
  NM_021451                               Phorbol-12-myristate-13-acetate-induced protein 1                                                Pmaip1/Noxa   2.66 ± 0.33           3.29 ± 0.49           5.63 ± 1.15
  NM_133234                               Bcl2 binding component 3                                                                         Bbc3/Puma     1.18 ± 0.31           3.00 ± 0.49           5.83 ± 1.25
  NM_024207                               Der1-like domain family, member 1                                                                Derl1         1.07 ± 0.31           1.57 ± 0.48           2.12 ± 0.54
  NM_010121                               eukaryotic translation initiation factor 2α kinase 3                                             Eif2ak3       1.44 ± 0.31           1.87 ± 0.48           2.18 ± 0.54
  NM_015774                               ERO1-like (*S. cerevisiae*)                                                                      Ero1l         1.06 ± 0.32           2.09 ± 0.48           2.63 ± 0.54
  NM_022331                               Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1   Herpud1       1.40 ± 0.36           2.28 ± 0.48           3.11 ± 0.54
  NM_011644                               Transient receptor potential cation channel, subfamily C, member 2                               Trpc2         1.81 ± 0.50           1.93 ± 0.57           2.02 ± 0.62
  NM_029572                               Thioredoxin domain containing 4 (endoplasmic reticulum)                                          Txndc4        1.15 ± 0.31           1.64 ± 0.48           1.83 ± 0.54
  NM_138677                               ER degradation enhancer, mannosidaseα-like 1                                                     Edem1         −1.66 ± 0.32          −1.91 ± 0.48          −1.55 ± 0.54
  Response to oxidative stress                                                                                                                           ▴16, *P* = 3.2 ^−2^   ▴16, *P* = 1.3 ^−2^   ▴16, *P* = 8.3 ^−5^
                                                                                                                                                         ▾N/A                  ▾N/A                  ▾N/A
  NM_013603                               Metallothionein 3                                                                                Mt3           1.04 ± 0.31           2.14 ± 0.48           2.07 ± 0.54
  NM_008706                               NAD(P)H dehydrogenase, quinone 1                                                                 Nqo1          1.33 ± 0.38           2.31 ± 0.66           3.03 ± 0.57
  NM_011034                               Peroxiredoxin 1                                                                                  Prdx1         1.28 ± 0.31           2.05 ± 0.48           2.08 ± 0.55
  NM_007453                               Peroxiredoxin 6                                                                                  Prdx6         1.07 ± 0.31           2.21 ± 0.48           2.48 ± 0.54
  NM_019913                               Thioredoxin 2                                                                                    Txn2          1.11 ± 0.31           1.59 ± 0.48           1.87 ± 0.54
  NM_029572                               Thioredoxin domain containing 4 (endoplasmic reticulum)                                          Txndc4        1.15 ± 0.31           1.64 ± 0.48           1.83 ± 0.54
  NM_015762                               Thioredoxin reductase 1                                                                          Txnrd1        1.61 ± 0.37           2.51 ± 0.56           3.40 ± 0.56
  NM_011198                               Prostaglandin-endoperoxide synthase 2                                                            Ptgs2         8.53 ± 0.77           25.00 ± 7.40          37.22 ± 1.70
  NM_010442                               Heme oxygenase (decycling) 1                                                                     Hmox1         18.03 ± 8.04          67.24 ± 1.05          86.75 ± 8.99
  NM_029688                               Sulfiredoxin 1 homologue (*S. cerevisiae*)                                                       Srxn1         4.72 ± 1.63           11.32 ± 0.48          12.87 ± 2.58
  NM_011847                               DnaJ (Hsp40) homologue, subfamily B, member 6                                                    Dnajb6        −1.16 ± 0.53          1.86 ± 0.60           1.86 ± 0.64
  NM_007869                               DnaJ (Hsp40) homologue, subfamily C, member 1                                                    Dnajc1        2.14 ± 0.41           3.93 ± 1.26           3.11 ± 0.59
  NM_010481                               Heat shock protein 9                                                                             Hspa9         1.18 ± 0.31           1.57 ± 0.48           2.31 ± 0.54
  NM_030704                               Heat shock protein 8                                                                             Hspb8         1.73 ± 0.55           4.65 ± 0.52           4.86 ± 0.58
  NM_013863                               BCL2-associated athanogene 3                                                                     Bag3          2.04 ± 0.36           2.77 ± 0.51           2.07 ± 0.57
  NM_009825                               Serine (or cysteine) peptidase inhibitor, clade H, member 1                                      Serpinh1      1.35 ± 0.34           4.77 ± 0.75           4.02 ± 0.54
  NM_019794                               DnaJ (Hsp40) homologue, subfamily A, member 2                                                    Dnaja2        −1.33 ± 0.31          −1.82 ± 0.48          −2.26 ± 0.54
  NM_018808                               DnaJ (Hsp40) homologue, subfamily B, member 1                                                    Dnajb1        −1.80 ± 0.31          −2.04 ± 0.48          −1.89 ± 0.54
  NM_008300                               Heat shock protein 4                                                                             Hspa4         −1.00 ± 0.31          −2.27 ± 0.48          −1.89 ± 0.54
  NM_178385                               Tubulin-specific chaperone c                                                                     Tbcc          −1.34 ± 0.34          −2.55 ± 0.49          −3.31 ± 0.55
  NM_001033149                            Tetratricopeptide repeat domain 9                                                                Ttc9          −1.41 ± 0.31          −2.14 ± 0.48          −1.75 ± 0.54
  Ubiquitin mediated proteolysis                                                                                                                         ▴24, *P* = 2.3 ^−5^   ▴21, *P* = 1.8 ^−4^   ▴21, *P* = 1.8^14^
                                                                                                                                                         ▾17, *P* = 8.9 ^−3^   ▾36, *P* = 4.4 ^−7^   ▾36, *P* = 4.1 ^−7^
  NM_028288                               Cullin 4B                                                                                        Cul4b         1.23 ± 0.32           1.67 ± 0.48           2.16 ± 0.54
  NM_176848                               F-box protein 2                                                                                  Fbxo2         1.32 ± 0.33           2.80 ± 0.48           3.83 ± 0.54
  NM_172721                               F-box and WD-40 domain protein 8                                                                 Fbxw8         3.08 ± 0.60           5.42 ± 1.58           4.86 ± 0.68
  NM_026101                               Hect domain and RLD 4                                                                            Herc4         1.16 ± 0.46           1.37 ± 0.71           1.95 ± 0.60
  NM_026557                               Ring finger and CHY zinc finger domain containing 1                                              Rchy1         1.23 ± 0.31           1.76 ± 0.48           2.22 ± 0.54
  NM_029438                               SMAD specific E3 ubiquitin protein ligase 1                                                      Smurf1        1.22 ± 0.38           3.13 ± 0.61           4.18 ± 0.56
  NM_019719                               STIP1 homology and U-Box containing protein 1                                                    Stub1         −1.21 ± 0.33          1.38 ± 0.49           1.48 ± 0.55
  NM_011965                               Proteasome (prosome, macropain) subunit,α type 1                                                 Psma1         1.14 ± 0.37           1.81 ± 0.51           1.64 ± 0.56
  NM_011184                               Proteasome subunit C8 (Psma3)                                                                    Psma3         1.35 ± 0.61           2.13 ± 0.52           2.30 ± 0.61
  NM_013585                               Proteasome (prosome, macropain) subunit,β type 9 (large multifunctional peptidase 2)             Psmb9         1.52 ± 0.39           2.07 ± 0.52           1.99 ± 0.57
  NM_026785                               Ubiquitin-conjugating enzyme E2C                                                                 Ube2c         1.37 ± 0.31           1.96 ± 0.48           −2.16 ± 0.54
  NM_173010                               Ubiquitin protein ligase E3A                                                                     Ube3a         1.38 ± 0.32           1.79 ± 0.48           2.20 ± 0.54
  NM_145400                               Ubiquitination factor E4A (UFD2 homologue, *S. cerevisiae*)                                      Ube4a         1.69 ± 0.67           1.99 ± 0.51           2.17 ± 0.56
  NM_177327                               WW domain containing E3 ubiquitin protein ligase 1                                               Wwp1          1.20 ± 0.31           1.67 ± 0.48           1.76 ± 0.54
  NM_172712                               Ubiquitin-like modifier activating enzyme 6                                                      Uba6          −1.82 ± 0.33          −2.17 ± 0.52          −1.96 ± 0.55
  NM_145420                               Ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homologue, yeast)                                     Ube2d1        −1.37 ± 0.31          −2.15 ± 0.48          −1.98 ± 0.54
  NM_025356                               Ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homologue, yeast)                                     Ube2d3        −1.23 ± 0.31          −2.38 ± 0.49          −1.80 ± 0.54
  NM_025985                               Ubiquitin-conjugating enzyme E2G 1 (UBC7 homologue, *C. elegans*)                                Ube2g1        −1.46 ± 0.31          −2.15 ± 0.48          −1.91 ± 0.54
  NM_016786                               Ubiquitin-conjugating enzyme E2K (UBC1 homologue, yeast)                                         Ube2k         −1.30 ± 0.33          −3.11 ± 0.49          −1.51 ± 0.55
  NM_027315                               Ubiquitin-conjugating enzyme E2Q (putative) 1                                                    Ube2q1        −1.79 ± 0.31          −2.76 ± 0.48          −3.48 ± 0.54
  NM_133907                               Ubiquitin protein ligase E3C                                                                     Ube3c         −1.47 ± 0.31          −1.90 ± 0.48          −1.73 ± 0.54
  NM_080562                               U box domain containing 5                                                                        Ubox5         −2.08 ± 0.33          −2.57 ± 0.51          −2.82 ± 0.55
  Glutathione metabolism                                                                                                                                 ▴5, *P* = 0.06        ▴12, *P* = 1.1 ^−4^   ▴5, *P* = 0.04
                                                                                                                                                         ▾N/A                  ▾N/A                  ▾N/A
  NM_008160                               Glutathione peroxidase 1                                                                         Gpx1          1.29 ± 0.32           1.89 ± 0.48           1.69 ± 0.54
  NM_010344                               Glutathione reductase                                                                            Gsr           1.29 ± 0.31           2.18 ± 0.48           3.49 ± 0.75
  NM_008180                               Glutathione synthetase                                                                           Gss           1.25 ± 0.43           3.19 ± 0.48           4.54 ± 0.54
  NM_008182                               Glutathione S-transferase,α 1                                                                    Gsta1         2.69 ± 1.32           10.45 ± 0.58          32.10 ± 7.71
  NM_008182                               Glutathione S-transferase,α 2 (Yc2)                                                              Gsta2         2.66 ± 0.71           8.68 ± 0.79           26.73 ± 9.86
  NM_010357                               Glutathione S-transferase,α 4                                                                    Gsta4         1.46 ± 0.34           5.78 ± 0.48           11.58 ± 1.15
  NM_010358                               Glutathione S-transferase, mu 1                                                                  Gstm1         1.21 ± 0.31           2.86 ± 0.48           3.27 ± 0.54
  XM_904332                               Glutathione reductase, mitochondrial precursor (GR) (GRase)                                      LOC630729     1.47 ± 0.36           2.15 ± 0.48           3.39 ± 0.54
  NM_019946                               Microsomal glutathione S-transferase 1                                                           Mgst1         1.09 ± 0.31           2.65 ± 0.48           2.47 ± 0.54
  Nitric oxide metabolism                                                                                                                                ▴63, *P* = 1.3 ^−6^   ▴21, *P* = 0.31       ▴19, *P* = 0.42
                                                                                                                                                         ▾45, *P* = 0.22       ▾44, *P* = 0.23       ▾44, *P* = 0.22
  NM_007494                               Argininosuccinate synthetase 1                                                                   Ass1          2.39 ± 0.42           4.16 ± 0.60           8.57 ± 1.56
  NM_013463                               Galactosidase, α                                                                                 Gla           1.73 ± 0.32           3.33 ± 0.48           2.76 ± 0.54
  NM_145953                               Cystathionase (cystathionine gamma-lyase)                                                        Cth           1.44 ± 0.51           2.66 ± 0.49           3.25 ± 0.54
  NM_008131                               Glutamate-ammonia ligase (glutamine synthetase)                                                  Glul          −1.08 ± 0.31          1.61 ± 0.48           −1.41 ± 0.54
  NM_013614                               Ornithine decarboxylase, structural 1                                                            Odc1          1.35 ± 0.31           1.87 ± 0.48           2.18 ± 0.54
  NM_008987                               Pentraxin-related gene                                                                           Ptx3          1.79 ± 0.32           2.68 ± 0.48           1.63 ± 0.54
  NM_013646                               RAR-related orphan receptor                                                                      Rora          1.78 ± 0.34           2.74 ± 0.66           2.94 ± 0.55
  NM_023141                               Torsin family 3, member A                                                                        Tor3a         1.71 ± 0.38           1.64 ± 0.52           1.81 ± 0.57

Numerical value after ▴/▾ indicates gene count up or down-regulated respectively at designated time-point, and *P* corresponds to modified Fisher\'s exact *P* value, EASE Score; the smaller the more enriched; usually *P* value is equal or smaller than 0.05 to be considered strongly enriched in the annotation categories. Default set for EASE Score Threshold (maximum probability is 0.1). All fold-change expressions are subjected to one-way [anova]{.smallcaps} analysis and significant at *P* \< 0.05. Data are expressed as fold-change ± S.E.

Cell death
----------

A significant number of cell death cascade-related genes demonstrated increase in gene expression which were altered from as early as 8 hrs ([Table 1](#tbl1){ref-type="table"}). Genes such as *Dapk2, Bcl2l11* and *Tnfrsf12a* demonstrated significant up-regulation at early 8 hrs nitric oxide post-treatment, with maintenance of consistently increasing expression throughout the time-course. Gene candidates potentially up-regulated from 15 hrs composed of *Angptl4, Dap* and *Ripk1*.

Cell survival
-------------

Cellular survival-promoting protein-encoding genes, particularly growth factors, for example *Bdnf, Igf1* and *Tgfb2* and their receptors, for example *Egfr* and *Fgfr2* showed elevated gene expression at early 8 hrs. To complicate matters, genes critical in neuronal regeneration after injury, such as *Nrn1* and *Nr4a2* also demonstrated an early increase in gene expression. Simultaneous transcriptional elevation also occurred to the tumour necrosis receptors associated factors (Trafs), for example *Traf3* and *Traf5*, pro-survival signalling molecules negatively regulated downstream of *Pawr*. Transcription factors such as *FBJ* osteosarcoma oncogene (*Fos* and *Fosb*) and *Jun oncogene* (*Jun* and *Junb*) which target pro-survival genes demonstrated substantial transcriptional up-regulation at 8 hrs.

### Mitotic cell cycle regulation

As demonstrated in [Table 1](#tbl1){ref-type="table"}, several genes involved in cell cycle progression such as the cyclins (*Ccna2, Ccnb1, Ccng1* and *Ccnl1*) cell division cycle homologues (*Cdc20, Cdc27* and *Cdc2l5*) and cyclin-dependent kinase (*Cdk7*) were mostly highly up-regulated at 15 hrs time-point. Simultaneously, most of the genes encoding for other subtypes of cyclins and cyclin-dependent kinases (*Cdks*) demonstrated significant persistent decrease in gene expression. On the contrary, genes that encode for proteins involved in the impediment of cell cycle progression, particularly from those of the p53-dependent pathway, such as *Trp53bp2, Gadd45a, Gadd45b, Gadd45g, Cdkn1a, Cdkn2b* and p53 endogenous inhibitor, *Mdm2* gene expression showed an up-regulation to counteract cell cycle re-activation.

### Endoplasmic reticulum stress

A significant transcriptional elevation of severe endoplasmic reticulum (ER) stress-induced pro-apoptotic genes was observed in nitric oxide mediated neuronal injury. These genes composed of *Ddit3, Cebpb* and *Pmaip1*, which were highly up-regulated at 8 hrs, and *Bbc3, Derl1, Herpud1, Ero1l* and *Trpc2* at 15 hrs NOC-18 post-treatment as shown in [Table 1](#tbl1){ref-type="table"}.

### Calcium homeostasis and binding

With the activation of the calcium-dependent calpains ([Fig. 2B](#fig02){ref-type="fig"}), it was worthy to examine the regulatory trend of genes encoding for proteins involving in calcium ion homeostasis. Genes encoding for proteins involved in calcium homeostasis and binding were significantly up-regulated in nitric oxide mediated neuronal injury at 8 hrs ([Table 1](#tbl1){ref-type="table"}). Examples of these genes include *S100a1, S100a4, Anxa3, AnxA5, Fkbp9* and *Fkbp10*.

### Response to oxidative stress

In response to the cellular oxidative stress, antioxidant pathways were triggered perhaps in an attempt to rescue to the neuron from oxidative stress-related cell death. These genes consisted of *Ptgs2, Hmox1* and *Srxn1*, which were up-regulated at 8 hrs and *Mt3, Nqo1* and peroxiredoxins (*Prdx1* and *Prdx6*) at 15 hrs. Furthermore, a handful of genes that encodes for chaperone proteins to alleviate cellular stress in response to aberrant protein formation were induced at 15 hrs in nitric oxide mediated neuronal injury ([Table 1](#tbl1){ref-type="table"}). These genes composed of *Dnajb6* and *Dnajc1* (*Hsp40*), *Hspa9* (*Hsp70*), *Hspb8* (*Hsp22*) and *Serpinh1* (*Hsp47*).

### Ubiquitin-mediated proteolysis

As nitric oxide is able to trigger protein modifications, it is important to ensure functionality of the ubiquitin--proteasome system (UPS) to perform the necessary protein clearance to reduce aberrant protein buildup. A significant proportion of UPS-related genes underwent significant and vast transcriptional regulation in nitric oxide mediated neuronal injury. Most ubiquitin-conjugating enzymes involved in ligation of ubiquitin protein/polypeptide destined for degradation (*e.g. Ube2c, Ube2d1, Ube2g1* and especially *Ube2q*) were significantly down-regulated, whereas others (*e.g.* ubiquitin ligases: *Siah2, Smurf1* and *Ube3a*) demonstrated transcriptional up-regulation. However, genes encoding for proteasome subunits *Psma1, Psma3* and *Psmb9* still demonstrated elevated gene expression. Time-point-specific statistical analyses using modified Fisher\'s exact *P* value demonstrated a statistical significant suppression of gene expression among UPS members, an indication of UPS dysfunction.

### Glutathione metabolism

Consistent with reports that glutathione (GSH) showed neuroprotective against nitrergic neuronal injury through sequestration of nitric oxide by formation of nitrosoglutathione (GSNO), remarkably increases in transcriptional expression of GSH metabolism related proteins (*e.g. Gpx1, Gsr, Gsta1, Gsta2* and *Gsta4*) were observed and documented in nitric oxide global gene profile.

### Nitric oxide metabolism

Genes encoding for proteins participating in nitric oxide involved multistep metabolic pathways such as urea cycle (*Ass1, Gla, Ptx3* and *Tor3a*) were highly up-regulated from the early 8 hrs time-point.

Validation of microarray analysis
---------------------------------

Microarray data were validated *via* Western blotting and real-time PCR and indicated a high degree of reliability and specificity. Immunoblot analyses ([Table 2](#tbl2){ref-type="table"}) and real-time PCR data ([Table 3](#tbl3){ref-type="table"}) both confirmed the differential expression profile induced by 0.5 mM NOC-18 treatment.

###### 

Immunoblotting validation of microarray data performed on 24 hrs 0.5 mM NOC-18-treated murine primary cortical neuron culture

  --
  --

###### 

Real-time PCR-based validation of microarray data on 24 hrs 0.5 mM NOC-18-treated murine primary cortical neurons

  **GenBank**   **Gene title**                               **Symbol**   **Microarray (24 hrs)**   **Real-time PCR (24 hrs)**
  ------------- -------------------------------------------- ------------ ------------------------- ----------------------------
  NM_020581     Angiopoietin-like 4                          Angptl4      2.63 ± .57                4.56 ± 0.69
  NM_007837     DNA-damage inducible transcript 3            Ddit3        7.10 ± 0.79               5.05 ± 0.70
  NM_011817     Growth arrest and DNA-damage-inducible 45λ   Gadd45g      8.80 ± 0.54               14.64 ± 0.75
  NM_010442     Heme oxygenase (decycling) 1                 Hmox1        86.75 ± 8.99              61.54 ± 1.67
  NM_030704     Heat shock protein 8                         Hspb8        4.86 ± 0.58               4.73 ± 0.98
  NM_011198     Prostaglandin-endoperoxide synthase 2        Ptgs2        37.22 ± 1.70              36.84 ± 0.87

Data are expressed as fold-change ± S.E. Each real-time PCR probe data is representative of three independent replicates.

Discussion
==========

The global gene profiling in this study reflects the simultaneous transcriptional activation and/or inhibition of multiple signalling cascades in nitric oxide mediated neuronal injury wherein 3672 probe sets demonstrated at least ±1.5-fold change in a minimum of one of three time-points (8, 15 and 24 hrs). These data provides an overview of the multi-interactive functions of nitric oxide with induction and inhibition various signalling pathways during the course of its induction of neuronal death. We found recruitment of several biological processes, including apoptotic cell death, survival, cell cycle, ER stress, antioxidative stress response, energy production, ubiquitin-mediated proteolysis, GSH and nitric oxide metabolism. As demonstrated in our study, the final neuronal decision to undergo cell death or survival is determined by the net coordinated effect between the pro- and antiapoptotic proteins. The evidence from our study further confirms the role that nitric oxide plays in the exacerbation of neuronal injury, thus highlighting the importance of its contribution to the pathogenesis of several neurodegenerative diseases where severe cellular oxidative stress is frequently experienced \[[@b19]\]. An understanding of the multiple mechanisms of nitric oxide mediated neuronal injury is advantageous for the better identification of potential biological targets in the intervention of neurodegenerative disease progression. Indeed, we have been able to provide major insights towards such a goal, including the revelation of the major cellular mechanisms contributing to the nitrergic neuronal injury and their temporal patterns of recruitment.

Time-course of gene profiling in relationship to cellular signalling
--------------------------------------------------------------------

Based on temporal recruitment of over-represented biological processes, we are able to postulate an overview of nitric oxide induction of neuronal death formulated upon the temporal pattern of transcriptomic changes ([Fig. 5](#fig05){ref-type="fig"}).

![Time-course analysis of nitric oxide global gene profile demonstrates the sequential activation and/or inhibition of the respective cellular signalling cascades upon nitric oxide entry into the neuron in nitric oxide mediated neuronal injury.](jcmm0016-0041-f5){#fig05}

Early- and medium-term events (*8--15 hrs processes*)

1.  Nitric oxide, a membrane-permeable gas diffuses through the cellular membrane.

2.  \(a\) Because of its excess presence, the nitric oxide metabolic pathways such as the urea cycle are activated in an attempt to remove the exogenous nitric oxide. Evident from the transcriptomic profile of nitric oxide mediated neuronal injury, the *Ass1* gene which encodes for arginosuccinate synthase 1 in the urea cycle for removal of excess nitric oxide, was especially up-regulated at the early 8 hrs time-point. (b) Simultaneously, because of its thermodynamic instability, nitric oxide interacts with other cellular gaseous molecules or ROS to form highly reactive free radicals and nitrergic free radical species (•NO~2~, •NO and ONOO^−^).

3.  These radicals and ions induced genotoxic damage and protein modifications, leading to increase oxidative stress. (a) Further, oxidative stress-mediated homeostatic ionic imbalance leads to increase Ca^2+^ cytosolic influx from intra- and extracellular compartments. In fact, perturbed Ca^2+^ ion homeostasis is obvious from nitric oxide transcriptomic profile with increase in gene expression of Ca^2+^-dependent proteins including pro-apoptotic serine/threonine kinase *Dapk2* ([Table 1](#tbl1){ref-type="table"}: Cell death), annexins and *S100* and *FK506* calcium binding proteins. This finding implies an occurrence of excitotoxic event with an increase in intracellular Ca^2+^ level, leading to activation of Ca^2+^-activated proteins such as calcineurin and calpains ([Fig. 2](#fig02){ref-type="fig"}), which mediated cleavage of α-fodrin to 145/150 kD fragments.

4.  Electrophilic stress together with abundant presence of misassembled proteins in ER lumen, converged to ER stress. Also known as ER-associated degradation (ERAD), this system governs ubiquitin-dependent degradation of misfolded ER proteins mediated by ER proteins. Derl1, Herpud1 and Edem1 are ER stress-inducible proteins involved in ERAD which demonstrated significant elevated gene expression at 15 hrs post-treatment in nitric oxide mediated neuronal injury. Nitric oxide mediated ER stress is also prominent from the substantial increase in gene expression of ER stress-responsive pro-apoptotic genes particularly DNA-damage inducible transcript 3 (*Ddit3*), CCAAT/enhancer binding protein (*Cebpb*), phorbol-12-myristate-13-acetate-induced protein 1 (*Pmaip1*), Bcl2-binding component 3 (*Bbc3*; [Table 1](#tbl1){ref-type="table"}: ER stress). (C/EBP) β, which was highly up-regulated at the early 8 hrs NOC-18 post-treatment. Dimerization of Ddit3 protein with its partner, Cebpb protein, forms a repressor complex, which inhibits transcription of survival-promoting genes. Bbc3, also known as p53-upregulated modulator of apoptosis (Puma), together with Pmaip1 (Noxa), are p53-mediated ER stress responsive genes as they encode BH3-only proteins, pro-apoptotic members of the Bcl-2 family required to initiate apoptosis through displacement of Bcl2 and Bcl-xL inhibitory interactions with the pro-apoptotic proteins Bax and/or Bak facilitating mitochondrial outer membrane permeabilization and cytochrome *c* release \[[@b33]\].

5.  Cellular stress leads to activation of Hsps and chaperones that work to alleviate the stress and restore homeostasis. It has been reported that nitric oxide can exert antiapoptotic effect through induction of cytoprotective gene expression \[[@b34]\]. As a result, several Hsps and chaperones (*e.g.* *Hspa9, Hspb8, Bag3* and *Serpinh1*), peroxiredoxins (*Prdx1* and *Prdx6*) and metallochaperone, *Mt3*, demonstrated significant increases in gene expression in nitric oxide mediated neuronal injury with *Ptgs2, Hmox1* and *Srxn1* being especially highly up-regulated ([Table 1](#tbl1){ref-type="table"}: Response to oxidative stress).

6.  Concomitantly, the pro-survival pathways such as growth factor signalling pathways are activated to promote cell preservation. Several of these genes play multifunctional roles in the antiapoptotic process. Birc6 (also known as Bruce), which demonstrated elevated gene expression from 15 hrs ([Table 1](#tbl1){ref-type="table"}: Cell survival), is a trans-Golgi peripheral membrane protein that functions as an effective inhibitor of apoptosis (IAP) by inhibition of caspase activity through its Bir domain \[[@b35]\]. It also contains an intrinsic E2/E3 ubiquitin ligase activity that targets Smac for degradation \[[@b35]\]. Deletion of the C-terminal end of Birc6 including the Bir domain resulted in increased p53 expression and nuclear localization with concomitant activation of mitochondrial-dependent apoptosis \[[@b36]\]. The tumour necrosis factor receptor associated factors (Trafs) were significantly up-regulated at 8 hrs. Traf5 have been reported to be involved in Tnf-induced nuclear factor κB (NF-κB) activation, resulting in increased transcriptional activity of pro-survival genes and subsequent protection from cell death \[[@b37]\].

    • Late events (*15--24 hrs processes*)

7.  As oxidative stress is further aggravated at the later stages, more Hsps and chaperones are activated. GSH metabolic pathway, the strong mammalian antioxidant signalling cascade, also comes into play. Correspond to genes encoding Hsps and molecular chaperones, members of the GSH pathway including glutathione peroxidase 1 (*Gpx1*), glutathione reductase (*Gsr*) and glutathione S-transferase (*Gst*) also demonstrated extensive up-regulation in nitric oxide mediated neuronal injury from as early as 8 hrs ([Table 1](#tbl1){ref-type="table"}: GSH metabolism) furthering validating the early occurrence of oxidative stress imposed by high levels of ROS. Gst genes, especially those encoding the α class (*Gsta1, Gsta2* and *Gsta4*), were highly up-regulated up to multiple of 10-folds gene expression. Gsts are involved in the detoxification of a wide variety of substrates through conjugation of reduced GSH to the electrophilic centre of the compound *via* a sulfhydryl group. Moreover, the glutathione synthase (*Gss*) involved in GSH biosynthesis also demonstrated elevated gene expression at 15 hrs, a further indication of intense cellular oxidative stress.

8.  As the extent of DNA damages becomes increasingly severe, coupling with strong mitogenic signal transduction to promote cell cycle re-activation, the p53 signalling pathway is brought into the picture to inhibit cell cycle re-entry and enhance the cell death progression. *In vitro* \[[@b38]\] and *in vivo* \[[@b39]\] studies have shown that terminally differentiated neurons destined for cell death are able to replicate DNA. A study by Kruman *et al.* \[[@b40]\] further confirmed that cell cycle re-activation is a vital component of DNA damage response of post-mitotic neurons that can result in apoptosis. Several cell cycle phase progression genes such as cyclins (*Ccna2, Ccnl1* and *Ccnt2*) cell division cycle homologues (*Cdc20, Cdc27, Cdc2l5* and *Cdc73*), FBJ osteosarcoma oncogene (*Fos* and *Fosb*) and Jun oncogene (*Jun* and *Junb*) showed significant up-regulation in nitric oxide mediated neuronal injury. However, attempt to revive the cell cycle machinery was counteracted by the activation of the p53 signalling pathway, as evident by gene up-regulation of its binding partner (*Trp53bp2*), growth arrest and DNA damage-inducible (*Gadd45*) family, cyclin B1 (*Ccnb1*) and G1 (*Ccng1*) and cell-dependent kinase inhibitors (*Cdkn1a* and *Cdkn2b*), which were related to cell cycle progression and/or DNA damage response. Cdkn1a, commonly known as p21, is involved in the inhibition of critical Cdks activity by hindering their phosphorylation of downstream cell cycle substrate, thus leading to a blockade of cell cycle progression. *Gadd45a, Gadd45b* and *Gadd45g* interact with both Cdk1 and cyclin B1, to induce inhibition of the kinase activity of the Cdk1/cyclin B1 complex upon genotoxic stress resulting in G2/M cell cycle arrest \[[@b41]\].

9.  Oxidative stress results in impairment of the mammalian protein clearance machinery. With the mounting accumulation of aberrant proteins in the ER lumen, ER activates its ERAD response to increase protein turnover *via* the UPS route. As such, it is crucial that the cellular inherent protein clearance pathway is functioning optimally to handle the high rate of protein degradation. We have previously reported the presence of UPS dysfunction in nitric oxide mediated neuronal injury \[[@b42]\]. As shown in [Table 1](#tbl1){ref-type="table"}, ubiquitin-mediated proteolysis was impaired with the significant down-regulation of majority of the ubiquitin-conjugating enzymes which are crucial in the preparation of proteins for targeted degradation by the proteasomes.

10. With the increasing homeostatic imbalance inflicted by the perturbation of various biological processes that is beyond restoration, the neuron triggers the cell death machinery, sending itself to demise. When the relative effect of the pro-death molecules overwhelms that of the pro-survival components, the cell death machinery is triggered *via* the activation of multiple cell death signalling cascades including the mitochondrial-dependent cytochrome *c* mediated signalling pathway \[[@b43]\], p53-mediated apoptotic signalling pathway (discussed in early/medium-term processes) \[[@b44]\], and the Fas pathway.

Conclusion
==========

Our study has for the first time addressed concurrently the multiple signalling mechanisms regulated/affected by nitric oxide in its course of mediation of neuronal death. This global gene profiling represents a novel database in term of the temporal patterns of recruitment of signalling cascade to nitrergic neuronal injury. This global gene profile of nitric oxide mediated neuronal injury provides the very initial phase of screening of potential protein candidates whose gene expression can be inhibited or stimulated to form the basis for therapeutic interventions in several neurodegenerative disorders.
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